A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb

Chimeric antigen receptor T-cell immunotherapy (CAR-T) has shown remarkable efficacy in treating tumors of lymphopoietic origin. Herein, we demonstrate an effective CAR-T cell treatment for recurrent and malignant CD30-positive peripheral T-cell lymphomas (PTCL) has been demonstrated. The extracellu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yang, Chen, Dan, Lu, Ya, Dong, Shu-Chen, Ma, Rong, Tang, Wei-yan, Wu, Jian-qiu, Feng, Ji-Feng, Wu, Jian-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850188/
https://www.ncbi.nlm.nih.gov/pubmed/33514882
http://dx.doi.org/10.1038/s41417-021-00295-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850188/
https://www.ncbi.nlm.nih.gov/pubmed/33514882
http://dx.doi.org/10.1038/s41417-021-00295-8

Ejemplares similares